Welcome to our dedicated page for BillionToOne SEC filings (Ticker: BLLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BillionToOne, Inc. filings document the regulatory record for a public molecular diagnostics company commercializing QCT-based prenatal and oncology testing. Recent Form 8-K disclosures furnish operating results, financial guidance, Regulation FD presentation materials and executive compensation arrangements, including the company’s annual incentive plan and equity-based payment provisions.
Proxy materials describe annual meeting mechanics, stockholder voting matters, board governance and related governance disclosures. Together, the filings address the company’s clinical testing revenue categories, Class A common stock compensation framework, furnished earnings materials and governance matters relevant to its Nasdaq-listed operating-company status.
Issuer files a Form 144 notice of proposed sales of Class A shares under Rule 144. The filing lists multiple proposed dispositions by holders and option exercises dated 07/09/2026 and earlier sales in June and July 2026. The excerpt shows representative proposed transactions of 12,500 shares for proceeds of $1,576,275.93 and several recent sales including 26,500 for $3,203,733.13.
Shan Sakakibara submitted notices on a Form 144 to offer shares of Class A common stock. The filing lists proposed sales of 8,000 shares with gross amounts of $785,800 (dated 06/08/2026) and $880,000 (dated 06/24/2026). The filing also lists Pre-IPO shares of 4,000 (dated 01/07/2019) and a Stock Option Exercise entry of 4,000 shares (dated 07/09/2026). The document shows a numeric line of 41,442,834 and a value $1,000,000.00 in the securities table; those figures appear as ledger entries in the excerpt.
BillionToOne, Inc. Chairman and CEO Atay Oguzhan reported a mix of open-market sales and option exercises involving the company’s Class A Common Stock. The Form 4 shows Rule 10b5-1 plan sales totaling 38,750 shares, including shares held indirectly through his spouse, at weighted average prices generally between about $118 and $125 per share.
On the same date, Oguzhan also exercised stock options to acquire 26,250 shares of Class A Common Stock at an exercise price of $2.80 per share, converting derivative awards into direct share ownership while continuing to hold a remaining common stock position as reflected in the filing’s post-transaction share balances.
BillionToOne, Inc. officer Nancy JoAnn Johnson reported an open-market sale of 801 shares of Class A Common Stock at a weighted average price of $124.9137 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, indicating it was scheduled in advance. Following this transaction, she directly holds 21,099 shares, so the sale represents a small portion of her reported stake.
BLLN submitted a Form 144 notice reporting proposed sales of Class A shares. The filing lists a proposed sale of 12,500 Class A Pre-IPO shares (cash) dated 05/01/2024 and discloses recent sales by named holders in June 2026.
The excerpt includes sales during the past three months: 12,500 shares by Ezgi N. Akcinar Atay, 26,250 shares by Oguzhan Atay, and 2,500 shares by Atay 2021 Dynasty Trust, each with corresponding proceeds shown.
BLLN insiders submitted Rule 144 notices for sales of Class A shares. The filing lists a planned sale of 26,250 shares with a figure of $3,150,000.00 and an associated date of 07/06/2026. The excerpt also discloses recent sales in the past three months: 26,250 shares for $2,563,632.00 by Oguzhan Atay, 12,500 shares for $1,227,812.50 by Ezgi N. Akcinar Atay, and 2,500 shares for $245,562.50 by Atay 2021 Dynasty Trust.
Blln, Inc. notice of proposed resale under Rule 144 for Class A shares by affiliated holders. The excerpt lists recent or proposed sales including 2,500 Class A shares sold by Atay 2021 Dynasty Trust on 06/08/2026 for $245,562.50, 26,250 Class A shares sold by Oguzhan Atay on 06/08/2026 for $2,563,632.00, and 12,500 Class A shares sold by Ezgi N. Akcinar Atay on 06/08/2026 for $1,227,812.50.
BillionToOne, Inc. senior vice president of laboratory operations John Roderick ten Bosch reported an open-market sale of 1,416 shares of Class A Common Stock at $120.00 per share. The transaction occurred on June 29, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026, and he continues to hold 33,552 shares directly after the sale.
Nancy J. Johnson reported sales of Class A shares under Rule 144. The filing lists two transactions: 3,418 shares sold on 06/08/2026 for $339,347.28 and 10,582 shares sold on 06/09/2026 for $1,063,192.55. The notice also references 801 Class A pre-IPO shares dated 07/03/2020.
BillionToOne, Inc. has entered into a long-term lease for approximately 62,659 square feet of office and laboratory space at 3260 Whipple Road in Union City, California. The new facility is intended to provide additional laboratory capacity as test volumes have exceeded the company’s plan over the last year.
The space will be dedicated to oncology products and will more than triple the company’s oncology-dedicated laboratory space, expanding total facility space by about 16%. The lease is expected to commence on or about August 1, 2027, has an initial 12-year term, and includes a 10-year extension option at then-prevailing market rates.
Aggregate base rent over the 12-year term is approximately $46.7 million. The landlord will provide an initial 12-month rent abatement and a tenant improvement allowance of up to $12.5 million, and BillionToOne will pay a security deposit of $407,910, plus its pro rata share of operating expenses, taxes, assessments and fees.